Marie Alexander
Medical Cue, Inc./Fogarty Institute

Nikolai Aljuri
PROCEPT BioRobotics, Inc.

Julie Allen
Allen Partners, Ltd.

David R. Amerson
NeoTract Interventional Urology | Teleflex

D. Bommi Bommannan
MaxVal Group, Inc.

Leslie Bottorff
GE Ventures

Daniel Burnett
TheraNova, LLC

Tara Butler
Ascension Ventures

David Cassak
MedTech Strategist

Peng Cheng, Ph.D.
SV Tech Ventures

Andrew Cleeland
Fogarty Institute for Innovation (FII)

William E. Cohn, MD
Texas Heart Institute

Darlene Crockett-Billig
Experien Group, LLC

Gavin Duggan
Google Data Science

Linda Elkins
Gore Innovation Center

Chris Eso

Maurice Ferré

Justin Takashi Fukuyama
MedVenture Partners, Inc

Jonas Funk
L.E.K. Consulting, LLC

Akiteru Furukawa
Hoya Corporation

Mark Gelfand
Coridea, LLC

Conor Hanley 

Ames Gross 
Pacific Bridge Medical


James Heslin
Wilson Sonsini Goodrich & Rosati

David Hoffmeister
Wilson Sonsini Goodrich & Rosati

James Huie
Wilson Sonsini Goodrich & Rosati

Bev Huss
Qool Therapeutics, Inc.

J.C. “Kirt” Kirtland
Emergent Medical Partners

Tom Krummel, MD
Stanford Byers Center for Biodesign; Fogarty Institute

Philip LaFleur
Food and Drug Administration

Ted Lamson Ph.D.
Innovation in Medtech, LLC/MedTech Strategist

Christopher Letang
SRS Acquiom

Stephen Levin
Innovation in Medtech, LLC/MedTech Strategist

Scott Lovald

Hongbo Lu
Lilly Asia Ventures

Josh Makower
New Enterprise Associates

Juan-Pablo Mas
Action Potential Venture Capital

Scott McCall
Wilson Sonsini Goodrich & Rosati

Casey McGlynn
Wilson Sonsini Goodrich & Rosati

Vance B. Moore
Business Integration, Mercy Virtual

Jack Moorman
US-Japan MedTech Frontiers (USJMF)

Susan Morano
Johnson & Johnson Medical Devices

Bali Muralidhar
MVM Partners, LLP

Scott Murano
Wilson Sonsini Goodrich & Rosati

Philip Oettinger
Wilson Sonsini Goodrich & Rosati

Steve Parmelee
Wilson Sonsini Goodrich & Rosati


Jenell Paul-Robinson
MedTech Innovator

Donna Petkanics
Wilson Sonsini Goodrich & Rosati

Avi Raval
Perella Weinberg Partners

Ulrico Rosales
Wilson Sonsini Goodrich & Rosati

Renee Compton Ryan
Johnson & Johnson Innovation – JJDC, Inc. (JJDC)

Vahid Saadat
Arrinex, Inc.

Siddarth Satish
Gauss Surgical, Inc.

Elton Satusky
Wilson Sonsini Goodrich & Rosati

Peter Shagory
CONMED Corporation

Bernard Shay
Earlens Corporation

Brian Smith
RedCrow, Inc.

Mark Speers
Health Advances, LLC

Nicole Stafford
Wilson Sonsini Goodrich & Rosati

Jody K. Thelander
J.Thelander Consultant

Meg Thering
Wilson Sonsini Goodrich & Rosati

Fred Toney
Launchpad Digital Health

Rafael Torres
Varian Medical Systems

Takahiro “Taka” Uchida
Japanese Organization for Medical Device Development, Inc. (JOMDD)

Kwame Ulmer
Principal, Ulmer Ventures

Amit Vohra
Promaxo, Inc.

Kevin Wasserstein
Neurotechnology Innovations Translator (NIT)

Jay Watkins
Reflexion Medical

Roderick Young
Cyberheart, Inc.

Speakers Biographies


2Marie Alexander
CEO, Medical Cue, Inc./Fogarty Institute

Marie is a strong operations executive focused on building and growing companies in early stage markets. She excels at driving companies from the initial go to market and early revenue transitioning company to professional management. She has deep experience in monetizing data driven technology companies, and experience in later stage companies. She has extensive knowledge in numerous functional areas and has applied to breath of industries ranging from customer facing retail operations to Fortune 100 companies. She has exceptional business and human relations acumen and has a history of creating strong loyal teams based on development of community-based environment for employees.

2Nikolai Aljuri
Co-Founder, President and CEO, PROCEPT BioRobotics, Inc.

Dr. Aljuri is the principal architect of the AquaBeam System and its core Aquablation technology. Prior to the formation of PROCEPT he invented and developed the Chartis collateral ventilation assessment technology at Pulmonx that facilitated an effective therapeutic treatment for emphysema. At NASA Center for Quantitative Cardiovascular Physiology and Data Analysis he worked on the physiologic implications for astronauts in the manned space mission to Mars. Dr. Aljuri has a Dipl.-Ing. in electrical engineering from the Universität Fridericiana zu Karlsruhe (KIT) in Germany and holds a Ph.D. in Medical Physics from the Harvard-MIT Division of Health Science and Technology at the Massachusetts Institute of Technology (MIT).

2Julie Allen
Founder and Managing Director, Allen Partners, Ltd.

Julie Allen is the Founder and Managing Director of Allen Partners, Ltd. She works as a strategic executive search  partner with emerging growth CEOs, dedicated to the mission of helping their companies succeed. Her leadership is rooted in the philosophy that people matter, context is imperative, and diving into the hearts and minds of people is where the greatest insights are found.

Julie founded Allen Partners in 2003 after reaping awards for a MedTech practice she established in Chicago. In 2001, she witnessed the search industry fading from a personal, consultative approach, to a factory driven approach that was efficient but not effective. With this came 11th hour surprises, offers left in limbo, and CEOs spending too much time, money and emotional expense recruiting. Seeing a need, knowing that CEOs have one time to get it right, she started this firm to give them and their companies a better outcome.

Early in her career, she was a Director at Foote, Cone & Belding, a global advertising firm in Chicago. She also held leadership positions in marketing, brand management and operations at Walt Disney World and Disneyland Paris. She earned a BA from Central Michigan University.

2David R. Amerson
President and General Manager, Interventional Urology, at Teleflex, Inc.

Dave joined Teleflex in October 2017 through the acquisition of Neotract, Inc. At NeoTract, he served as President, Chief Executive Officer and as a member of its Board of Directors since July 2011.

From 2006 to 2011, Dave was Global Vice President, General Manager for the Urology division of Coloplast, a publicly traded medical equipment company based in Denmark. From 1990 to 2006, he worked at Mentor, a publicly traded medical device company, and he was Global Vice President of Sales and Marketing for the Urology division at the time Mentor was acquired by Coloplast in 2006. Prior to Mentor, he worked at Osbon Medical Systems, a private urological medical device company, in a variety of management roles.

Dave is a former board member of the Urology Society of America and the American Lithotripsy Society. He holds a M.B.A. from Argosy University and a B.A. in Political Science from the University of West Georgia.

Dave is based in Pleasanton, CA.

2D. Bommi Bommannan
Founder & CEO, MaxVal Group, Inc.

Bommi founded MaxVal in 2004 to help companies optimize the management of patent lifecycle and maximize the value of their patents. His initial efforts in monetizing patents in the life sciences arena has led to a sophisticated approach at MaxVal for processing patent portfolios in various sectors for monetization. Bommi has assembled a talented team that operates globally to develop high quality, cost-effective solutions for patent groups.

Bommi’s patent experience started as an inventor while a graduate student, then becoming a patent agent at his job as a research scientist, followed by various stints at the Bay area’s many prestigious law firms such as Morrison Foerster, Cooley Godward, and Thelen Reid & Priest and in-house at companies like Alza. Bommi’s exposure to patent practice at law firms and in-house has given him a unique perspective that has laid the foundation for many of the solutions offered by MaxVal.

Before founding MaxVal, Bommi was the CEO at NTERO Surgical, Inc., a medical device company that he co-founded with support from Menlo Ventures, where he learned to handle the challenges of raising capital, assembling a top notch team and developing products.

Bommi’s work experience includes research and management positions at Merck, Cygnus, and Alza. He is an inventor on more than 20 patents and has published more than 50 articles in scientific journals. He received his Ph.D. in Bioengineering from a joint program between UCSF and UC, Berkeley and his law degree (JD) from Stanford Law School (Order of the Coif). He is a registered patent attorney (USPTO and California).

2Leslie Bottorff
Managing Director, Healthcare, GE Ventures

Leslie invests in start-up companies in the healthcare industry, specializing in digital health and healthcare IT, medical device technology, and emerging business models. Leslie joined GE Ventures in 2014 after 16 years of experience in venture capital investing as Managing Director with ONSET Ventures. She works with GEV portfolio companies Neuronetics, Chrono Therapeutics, Digisight, Iora, Omada Health and Arterys. Board seats prior to GEV include Sadra Medical (acquired by Boston Scientific), and Spinal Concepts (acquired by Abbott Labs). Prior to venture investing, Leslie spent 19 years serving in various operating roles at both large corporations and small venture backed start-up companies including VP of Sales and Marketing at Medtronic CardioRhythm, VP of Marketing at Embolic Protection, Inc. (acquired by Boston Scientific) and key positions at start-ups Nellcor (now Medtronic/Covidien), Ventritex (acquired by St. Jude), Menlo Care (acquired by J & J), and GE’s Healthcare Division. She holds a Bachelor’s degree in biomedical engineering from Purdue University, and an MBA from Harvard Business School. Leslie has served on advisory boards or as guest faculty at several universities including Purdue, Stanford, and UC Berkeley.

2Daniel Burnett, MD
CEO, TheraNova, LLC

Dr. Burnett received his M.D. and M.B.A. degrees from Duke University and completed his residency at the Mayo Clinic.  He has worked briefly at the FDA and was a General Partner at a medical device focused venture capital firm from 2003-05. Dr. Burnett holds a medical license in California and he is an Associate Professor in the Department of Bioengineering at UCSF where he also acts as Industry Director for the Masters of Translational Medicine program. Since 2006 he has founded nine TheraNova spinouts which have collectively raised over $250M in capital.

In addition to his commercial efforts Dr. Burnett has been very active in the nonprofit community.  He has volunteered at the Haight Ashbury Free Clinic, participated in medical missions to Central America and formed two nonprofits, one to design medical devices for low to middle income countries (LMIC) and one to send unused supplies to LMICs.

2Tara Butler
Managing Director, Ascension Ventures

Tara Butler came to Ascension Ventures in 2002 after completing a residency in obstetrics and gynecology at Washington University in St. Louis. She primarily focuses on investments in the medical device and diagnostics sector. Tara has been a board member or observer at several Ascension Ventures portfolio companies, including Apama Medical, Augmenix, CHF Solutions, Confluent Surgical, CSA Medical, EBR Systems, EKOS Corporation, HemoSphere, Ivantis, MindFrame, Neurolutions, Ocular Therapeutix (NASD:OCUL), Stereotaxis (NASD:STXS), and TomoTherapy (NASD:TOMO). Prior to attending medical school, she held positions in business development at Medtronic, in finance at Honeywell and as a laboratory research assistant at the University of Pennsylvania School of Medicine. She holds a BS in Economics and an MBA from the Wharton School of Business at the University of Pennsylvania, and a Doctor of Medicine from the University of Pennsylvania School of Medicine.

2David Cassak
Editor-in-Chief, MedTech Strategist
David Cassak has more than 30 years of experience in the health care industry.  Prior to co-founding Innovation In Medtech, LLC, he served as Vice President, Content and Managing Director, Medical Devices for Elsevier Business Intelligence, A Reed Elsevier Company, now part of Informa Business Information, where he wrote extensively on the medical device industry for Windhover’s monthly publications, IN VIVO and START-UP.  He is also a frequent speaker before various companies and industry trade groups.

Prior to joining Elsevier, Cassak worked for nearly 20 years at Windhover Information Inc., a company he founded with his partner, Roger Longman, which spun out the publications business of The Wilkerson Group, a leading management consulting firm at the time.  Long known for publishing IN VIVO, widely recognized as the premier provider of business intelligence in the health care industry, Windhover launched a number of other successful publications, including START-UP: Emerging Medical Ventures, and The RPM Report: Regulation • Policy • Market Access. In 2004, Windhover acquired Medtech Insight, Inc., which published the MEDTECH INSIGHT: Medical Technology Market Intelligence newsletter.  While at Windhover/EBI, David also organized and produced numerous conferences around the world, including the Investment in Innovation (In3) medical device partnering conference series, as well as such pharma-focused conferences as Pharmaceutical Strategic Alliances, Euro-Biotech and BIO-Windhover.  In 2008, Windhover was acquired by Elsevier, which formed Elsevier Business Intelligence, combining the products of Windhover and F-D-C Reports, publishers of The Gray Sheet and The Pink Sheet, among other industry newsletters.

2Peng Cheng, PhD
Managing Partner, SV Tech Ventures

Peng Cheng was most recently the Co-Founder and General Partner of SV Tech Ventures, a Silicon Valley based venture capital firm focused on investing in early stage U.S. technology startups.  SV Tech Ventures have invested in more than 70 startups since its inception in April 2015.  In 2014, Peng also co-founded Weiming Angels, an angel investment community initially consisted mostly of Peking University Alumni.  He was founder and Managing Director of Brilliance Capital, a venture capital company focusing on investment in early stage technology companies, ranging from networking, wireless, semiconductor, biotech, and Medical, since 2001.

Peng was senior manager at Intel from 1990 to 2001.  He was involved in research and development of deep sub-micron device and processing, Silicon-on-Insulator, spacer gate, and Micro-Electro-Mechanical System (MEMS).  He is the holder of more than 30 US patents.

Peng received his Ph.D. in Physics from Stanford University in 1990 and B.S. in Physics from Peking University in 1985.

2Andrew Cleeland
President, Fogarty Institute for Innovation (FII)

Andrew Cleeland is the President of the Fogarty Institute for Innovation (FII), a nonprofit institution located on the El Camino Hospital campus in Mountain View and focused on providing entrepreneurs working on promising new medical therapies mentorship and access to expert intellectual, physical and financial resources to propel medical concepts from initiation to application.  Prior to joining FII, Mr Cleeland Cleeland worked at Medtronic following the acquisition of Twelve Inc. Prior to Twelve, he was the president and CEO of Ardian, the pioneer of renal denervation for hypertension, heart failure and other associated disorders. Medtronic acquired Ardian in 2011 in one of the largest venture-funded exits in medtech history.

2William E. Cohn, MD
Director, Minimally Invasive Surgical Technology, Texas Heart Institute

William E. Cohn, MD, is a Vice President of Medical Devices and Executive Director for the Center of Device Innovation in Houston, Texas at Johnson & Johnson. He is also a professor of surgery at Baylor College of Medicine and an adjunct professor of Bioengineering at both Rice University and the University of Houston. From 1993-1994, Dr. Cohn first served as a Clinical Fellow in the Cardiothoracic Surgery Department at Beth Israel Deaconess Hospital in Boston, Massachusetts. He then went on to serve as a Cardiothoracic Surgeon from 1994-2004 at Beth Israel Deaconess Medical Center and Director of Minimally Invasive Cardiac Surgery at Beth Israel Hospital from 2001-2004. Dr. Cohn joined the Texas Heart Institute in 2004. From 1994-2004 Dr. Cohn served as a professor of surgery at Harvard Medical School.

His major research interests include the development of new technology for decreasing the invasiveness of cardiac and vascular surgery and development of the continuous-flow totally implantable artificial heart. In 2011, Dr. Cohn and Dr. O. H. Frazier successfully implanted the first pulseless total heart replacement device in a human patient. Dr. Cohn has a passion for medical device development and has more than 90 US patents granted or pending and another 60 international patents for his medical innovations.

His numerous awards include an honorary doctorate in science from Oberlin College, the Distinguished Scientist Award, given by the MacDonald Fund, and the Edison Award for excellence in human-centered design and innovation for inventing the SentreHEART® Lariat® Suture Delivery Device. In 2000, Dr. Cohn was named the distinguished Inventor of the Year by the U.S. Intellectual Property Owners Association and in 2014, he was named Outstanding Inventor of the Year by the Houston IPO. In addition, in 2014 he received an award for the most Innovative Medical Device Startup of the year at the Innovations in Cardiovascular Interventions Conference in Tel Aviv for inventing the TVA Everlin q system for percutaneous creation of AV fistulas and for founding TVA Medical. In 2015, he was awarded a Lifetime Achievement Award for healthcare innovation by the Houston Technology Center.

He is a Venture Partner at Santé Health Ventures, and Chief Medical Officer of BiVACOR Inc. and Reliant Heart. Dr. Cohn graduated with a B.S from Oberlin College and his MD from Baylor College of Medicine.

2Darlene Crockett-Billig
Co-Founder & President, Experien Group, LLC

Darlene co-founded Experien Group with Michael J. Billig. During her 40+ year career in the medical device industry, Darlene has directed over 300 successful submissions, including PMAs, IDEs, 510(k)s, HDEs, de novos, Technical Files and Design Dossiers. She has been responsible for regulatory affairs, quality systems and clinical research activities for a myriad of products, including implantable and active implantable devices, combination products, in vitro diagnostics, and instruments. Darlene is an expert in validation testing, including sterilization (ethylene oxide, radiation, steam and dry heat) and aseptic processing.

Darlene is an expert in interpreting U.S. and international standards and regulations for clients. She additionally provides virtual executive leadership and strategic project support for client companies advancing U.S. Class I, Class II and Class III medical devices and combination products. For several clients, Darlene functions as the Acting Vice President of Regulatory, Quality and Clinical, representing the companies in interface with regulatory agencies, investors, and more. She has developed a fully-customizable, comprehensive Quality Management System for Experien Group clients.

2Gavin Duggan
Google Data Science

Gavin is a research scientist and senior software engineer in Google AI Healthcare, where he has been a member of the bootstrap team for three health-AI related projects.  Prior to joining Google, he published papers in applied data science research for metabolic modeling, biochemical etiology, and analytical infrastructure for the human genome project at Sick Kids.

2Linda Elkins
Chief Technology Officer, Gore Innovation Center

Linda Elkins’ career spans 17 years, in which she’s served in multiple roles at W. L. Gore & Associates. In the Sunnyvale, Calif. based Medical Products Division, Linda led new product development teams from ideation to commercial launch; drove technical resourcing for manufacturing engineering; and owns two patents, including work on endovascular repair of aneurysms approximate to side branch vessels. She made a short career pivot as a professional triathlete, where she competed in Ironman Hawaii multiple times as well as several International World Championship races. Linda earned an M.S. in both Biomedical and Mechanical Engineering from the University of Michigan, and a B.S. in Biomedical Engineering from the University of Notre Dame.

Linda dedicated the past two years to the creation and launch of the Gore Innovation Center in Silicon Valley, where she took it from its original concept to the facility’s execution, completion and launch. Now, she’s working to jointly develop products, technologies and business models where Gore materials can uniquely add value. Linda is focused on developing strategic partnerships with startups, corporations and academia that align or expand Gore’s current focus in the fabrics, medical, industrial and electronics industries.

2Chris Eso
Vice President, Coronary and Structural Heart Strategy, Growth and Business Development, Medtronic

Chris Eso is Vice President of Corporate Development for Medtronic, specifically covering the Cardiac and Vascular Group business units, including Cardiac Rhythm and Heart Failure (CRHF), Coronary and Structure Heart (CSH), and Aortic, Peripheral Vascular and endoVenous (APV). Chris joined Medtronic as the Senior Manager of Business Development in August of 2011. He oversaw Medtronic’s global inorganic growth strategies and opportunities for Coronary business, and was promoted in June of 2012 to expand his Business Development responsibilities to include the Renal Denervation business. In April of 2013, Chris was promoted to Director, overseeing Business Development functions and leading a team of professionals. In September of 2014, Chris was promoted to Senior Director, Business Development for the Coronary and Structural Heart business unit for Medtronic, and in February of 2016, Chris was promoted to Vice President of Corporate Development.

Chris has more than 18 years of successful professional experience, of increasing responsibilities, with the majority of his experience in a business/corporate development and strategy capacity within the pharmaceutical and medical device industries, in addition to Medtronic, including Allergan, Watson, Agilent Technologies and Peregrine Pharmaceuticals, where he was Vice President of Business Operations.

Chris holds an MBA from Concordia University and BA in Public Relations, Communications from California State University, Fullerton.

2Maurice R. Ferré, MD
CEO and Chairman of Board, INSIGHTEC

Maurice R. Ferré MD is INSIGHTEC’S CEO and Chairman of the Board of Directors. Dr. Ferré brings over 20 years of experience in the medical device industry.

Before INSIGHTEC, Dr. Ferré served as Chairman of the Board and CEO of MAKO Surgical Corp, a transformational robotic surgical company that he co-founded in 2004. The company was IPO’d in 2008 and recently sold to Stryker Corp. for $1.65 billion in 2013. Prior to MAKO, Dr. Ferré was Founder, CEO and President of Visualization Technology Inc. (1993-2002). VTI became the world leader in image guided surgery for ENT, cranial and orthopedic procedures. The Company was acquired by GE Healthcare in 2002.

Dr. Ferré received his Doctor of Medicine and Master of Public Health from Boston University in 1992. He was also the recipient of the prestigious Ernest & Young 2007 Entrepreneur of the Year Award. Dr Ferré is currently active on the following boards: Advamed, The Everglades Foundation and Boston University.

2Justin Takashi Fukuyama
Partner, MedVenture Partners, Inc

Justin Takashi Fukuyama is a partner at MedVenture Partners, Inc., a venture capital firm based out of Tokyo, Japan, which invests in seed to early stage start-ups in the medical devices sector both inside and outside of Japan. MedVenture Partners was established in October 2013 to help build the foundation for a medical device incubation ecosystem in Japan.

Justin has spent the last 14 years of his career in the medical device industry. Prior to joining MedVenture Partners, Justin worked in various capacities at Boston Scientific Corporation and Johnson & Johnson, including regulatory affairs, sales & marketing, and new business development. Justin holds a B.S. in Biomedical Engineering and an M.S. in Regulatory Science from the University of Southern California, and an MBA from Kyoto University in Kyoto, Japan.

2Jonas Funk
Managing Director and Partner, L.E.K. Consulting, LLC

Jonas Funk is a Managing Director and Partner in L.E.K. Consulting’s Chicago office. He has more than 17 years of experience at L.E.K. and has directed hundreds of consulting engagements, primarily focused on growth strategy and mergers and acquisitions support in the medtech and life sciences industries. Jonas has served in the L.E.K. Chicago and San Francisco offices. In addition, he co-founded the Tokyo office and has assisted dozens of clients in developing their Asian strategies. He holds a Bachelor of Arts in Economics from Carleton College, and his work in economics has been published in leading academic journals and national newspapers.

2Akiteru Furukawa
General Manager, Corporate Venture Capital Group, Hoya Corporation

Mr. Furukawa is the General Manager of the Corporate Venture Capital Group for Hoya Corporation, a global leader and supplier of innovative high-tech and medical products. He has served in a number of executive positions at Hoya, where he has worked since 1988. He held a variety of laser device management roles including medical lasers in R&D, manufacturing, operations and sales. Additionally, he was a head of the Planning Department for the Corporate R&D center. He started Hoya’s Corporate Venture Capital Group in 2012 with the focus to place investment in early stage medical device start-ups, especially in the field of Ophthalmology, ENT, and GI (Eye to GI). Current portfolio companies are based in US, Singapore, Israel and Japan. He currently serves as a board member for five start-ups. He was a board member of InnFocus at the time of acquisition by Santen.

Prior to joining Hoya, he was a designer for Wire dot/BJ Printer electric circuits at Canon. Mr. Furukawa holds a Bachelor of Science in Electronic Engineering from Chuo University in Tokyo.

2Mark Gelfand
Managing Partner and Chief Technical Officer, Coridea, LLC

Mr. Gelfand has more than 25 years of experience developing medical devices in academic, startup and corporate environments. His expertise is in integrative physiology, systems engineering and intellectual property. With Dr. Levin, he co-founded Axon Therapies, Soffio Medical, Cibiem, CHF Solutions, Ardian and Respicardia and served as the chief technology officer to those ventures.

Mr. Gelfand also worked at Nellcor Puritan Bennett, the world’s leading respiratory device company, where he was responsible for the architecture development of a new ICU ventilator platform. Prior to Nellcor, he was co-founder and chief technology officer of CardioLogic Systems Inc., where he was responsible for the development of the Vest CPR device designed to treat cardiac arrest. The successor to that device is now marketed as AutoPulse® by Zoll Medical. From 1987 to 1992, Mr. Gelfand was senior research engineer in the division of cardiology at The Johns Hopkins School of Medicine, responsible for the development of several concept-level medical devices.

Mr. Gelfand is an author and co-author of more than 100 issued U.S. patents in the fields of heart failure, resuscitation, sleep apnea and dialysis. He holds master’s degrees in electrical engineering from St. Petersburg Institute of Technology and received graduate-level training in physiology at The Johns Hopkins School of Medicine.

Mr. Gelfand is an adjunct associate professor of biomedical engineering at Columbia University, lecturers and mentors students at Mount Sinai and Johns Hopkins Medical Schools and serves on the External Advisory Board of the Johns Hopkins University Center for Bioengineering Innovation & Design.

2Paul Grand 
CEO, MedTech Innovator 

Paul founded and has managed MedTech Innovator since it started as program within RCT Ventures in 2013. In 2016, with the financial support of RCT and other sponsors, Paul left to run MedTech Innovator as a stand-alone company. In his previous role as Managing Director for RCT Ventures, the investment arm of Research Corporation Technologies, Inc., Paul’s focus was on medical device investments and programs to encourage innovation and commercialization of early-stage technologies at institutions like UCLA, Stanford, USC, UCSF, UCSD, CU, Utah, and UW. Prior to joining RCT, Paul founded and operated eight hightech, medical device and biotechnology companies. In the life sciences, Grand was co-founder and VP of Operations of Imagine Pharmaceuticals and co-founder and CEO of MicroSurgeon in Los Angeles.

2Ames Gross
President and Founder, Pacific Bridge Medical

Mr. Gross founded Pacific Bridge Medical in 1988 and has helped hundreds of medical companies with business development and regulatory issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. In 2008, Medical Device and Diagnostic Industry (MD&DI) magazine named Mr. Gross one of the top 100 executives in the medical business. Mr. Gross is a frequent contributor of articles on Asian medical issues for Clinica (England), MD&DI (Los Angeles), and other medically oriented journals. He has been a featured speaker on the Asian medical markets at the Medical Design and Manufacturing (MD&M) shows, the Medtrade Home Health Care Exhibition, the Regulatory Affairs Professional Society’s annual and regional meetings, and a variety of other medically oriented meetings and conferences.

Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.

2Conor Hanley

Conor Hanley is CEO of FIRE1. Headquartered in Dublin, Ireland, FIRE1 is a connected medical device solutions company dedicated to improving outcomes for people suffering with chronic diseases. Its first product is a novel remote monitoring solution to improve outcomes for Heart Failure patients. FIRE1 originated from The Foundry in Menlo Park with investors including Medtronic, NEA, Lightstone Ventures, GILDE, GIMV and Seventure.

Conor Hanley previously worked with ResMed where he has held a number of senior management positions including leading up Chronic Disease management solutions globally, the global Cardiology business unit and the Ventures and Initiatives global business unit for corporate investments and accelerating new businesses.

Prior to ResMed, Conor was CEO and co-founder of BiancaMed, which was acquired by ResMed in 2011. BiancaMed grew as a spin out from University College Dublin and commercialised a novel, non-contact method to provide connected health solutions for wellness and medical applications. Over 7 years, he led a team that grew the company through three rounds of venture funding from top-tier international venture funds, launching products in Japan and USA (selling in major retailers, including the Apple store) and building the supply chain with mass production in China.

Conor was awarded a PhD in Chemical Engineering from the University of Pennsylvania, an MBA from INSEAD, and a B.Eng. from University College Dublin. Conor has completed the Leadership4Growth program at Stanford University and is a qualified Chartered Director from the Institute of Directors, UK.

2James Heslin
Partner, Wilson Sonsini Goodrich & Rosati

For more than 20 years, James Heslin has focused on helping medical device companies protect and enforce their domestic and international intellectual property rights, as well as advising venture capitalists who invest in medical technology companies. Jim’s medical and surgical device clients span a broad array of technologies, including angioplasty, atherectomy, stent delivery, arthroscopic treatments, suturing devices, ultrasound imaging and therapy, gynecological devices, minimally invasive surgical equipment, implantable hearing aids, drug delivery systems, orthodontics, orthopedics, and diagnostics.

In addition, Jim has extensive experience in investor due diligence, portfolio evaluation, licensing matters, and the preparation of patent validity and infringement opinions. He also counsels clients regarding in-house intellectual property protection programs.

Prior to joining the firm, Jim was the founder and leader of the medical device technology patent group at Townsend and Townsend and Crew (now Kilpatrick Townsend). He also served as general counsel for Align Technology.

Jim currently serves as a member of the firm’s Policy Committee.

2David Hoffmeister
Partner, Wilson Sonsini Goodrich & Rosati

David Hoffmeister is a partner at Wilson Sonsini Goodrich & Rosati, where he plays a major leadership role in the firm’s drug and device regulatory and healthcare law practice. David was named as one of the “25 Leading Biotech Attorneys” in California in 2011 by the Daily Journal, and is recognized as one of the leading food and drug regulatory lawyers in the country.

David brings more than 25 years of experience in drug and device regulatory and healthcare law to the firm. He represents pharmaceutical, biotechnology, medical device, diagnostic, and dietary supplement clients, advising them on a variety of regulatory and healthcare issues, such as strategies for obtaining FDA product approvals and clearances, recalls, labeling, and claim support for advertising and promotional materials. He has also conducted numerous internal investigations for pharmaceutical and medical device companies involving fraud and abuse, advertising and promotional practices, and clinical research practices.

Before joining Wilson Sonsini Goodrich & Rosati, David was senior counsel for drug and device law at Syntex U.S.A., Inc., where his primary focus was advising senior management on worldwide issues affecting the ability of the corporation and its affiliates to develop, manufacture, and distribute pharmaceutical, device, diagnostic, and over-the-counter drugs in compliance with the Federal Food, Drug, and Cosmetics Act, as well as implementing regulations and applicable state and federal healthcare laws.

2James Huie
Partner, Wilson Sonsini Goodrich & Rosati

James Huie is a corporate and securities partner in Wilson Sonsini Goodrich & Rosati’s SOMA office. James advises life sciences and technology companies on general corporate matters, mergers and acquisitions, initial public offerings, strategic partnerships, and private equity and debt financings. He also has extensive experience in representing venture capital firms and other investors in private equity and debt financings.


2Bev Huss
President & CEO, Qool Therapeutics, Inc.

Beverly Huss joined Qool Therapeutics as President and CEO in September 2013. Previously, Beverly was President and CEO of Vibrynt, Inc. a company that developed a novel minimally invasive therapeutic device for treatment of morbid obesity. Prior to this, Beverly was with Santa Clara, California-based Guidant since 1986, fulfilling a variety of executive roles within the company’s various medical device divisions. She managed the worldwide Endovascular Solutions business as President and quadrupled worldwide revenues to $150 million for the carotid and peripheral vascular business in four years.

Prior to this Beverly held several executive level positions as Vice President of Guidant’s Canada and Latin America operations, Vice President of Vascular Intervention Global Marketing and Vice President of the Stent Business Unit where she built the company’s coronary stent business, a market leader for 27 of 28 quarters. Earlier in her career, Beverly held engineering positions at both Honeywell Defense Systems Division and Jones and Laughlin Steel. Additionally, she served as chairman of the Silicon Valley American Heart Association and as a senior advisor to Pervasis Therapeutics, a Cambridge, MA based cell therapy company.

Beverly holds a M.S. in technology management from Pepperdine University and a B.S. in metallurgical engineering from the University of Illinois. Beverly has several patents to her credit in the cardiovascular and obesity medical device areas. Beverly serves on the board of Surefire Medical, Ciel Medical, and the University of Illinois Material Science and Engineering steering Committee and Biomedical Engineering Steering Committee. She previously served on the boards of Ulthera, Dade Behring, Inc., Wright Medical Inc., and Artes Medical. She is a mentor in the Stanford University Biodesign Fellowship Program. Beverly was the recipient of the 2013 University Of Illinois College Of Engineering Alumni Award for distinguished leadership in the medical device industry.

2J.C. “Kirt” Kirtland
Managing Director, Emergent Medical Partners

Mr. Kirt Kirtland is an experienced CEO, medical device management professional, and investor. With over 25 years of medical device experience and over 15 years of CEO experience, Mr. Kirtland supports portfolio companies with a strong understanding of the clinical, operational, legal, and financial aspects of growing life science companies. Prior to serving as CEO, Mr. Kirtland held a variety of medical device management roles in operations, marketing, engineering and sales. Mr. Kirtland’s expansive medical device management experience includes a wide array of specialties including orthopedics, gynecology, urology, cardiology, gastroenterology and otolaryngology. Mr. Kirtland has negotiated acquisitions, served as a board member and observer at portfolio companies, and sourced and investigated investments in conjunction with other partners. Mr. Kirtland received his M.B.A. from Stanford University School of Business and his B.S. in biology from Stanford University. Mr. Kirtland is a Retired Captain in US Navy.

2Tom Krummel, MD
Co-Director, Stanford Byers Center for Biodesign; Fogarty Institute

Dr. Krummel joined the Board of Directors Fogarty Institute in 2014, and shortly thereafter was appointed chairman. He is Co-director of the Stanford Byers Center for Biodesign since 2002. He holds the Emile Holman Professorship and is chair emeritus of the Department of Surgery at Stanford University School of Medicine as well as Susan B. Ford Surgeon-in-Chief Emeritus at Lucile Packard Children’s Hospital.

Throughout his distinguished career as a pediatric surgeon, Dr. Krummel has been a pioneer-first in the early adoption of ECMO in treatment of neonatal cardiopulmonary collapse. Thereafter he drove the application of information technology in simulation-based surgical training and surgical robotics, serving as an early advisor to ComputerMotion, Inc. He directed one of the first National Institute of Health Phased Innovation programs that developed collaborative-based simulation systems and was awarded two Smithsonian Information Technology Innovators Awards for his work.

Tom is a vigorous consultant to the medical device industry, serving on multiple Scientific Advisory Boards and Boards of Directors. He has helped orchestrate four successful exits and has 20 more early to late stage companies in his portfolio.

As a leader, Tom has served as  President of the International Scientific Committee at IRCAD- University of Strasbourg, France, Chair of the BOD of the American Pediatric Surgical Foundation and a Board member at the Morgridge Institute at the University of Wisconsin.

2Philip LaFleur
Food and Drug Administration

LCDR Lafleur trained as a Physician Assistant at Trevecca Nazarene University, graduating in 1998. After joining the United States Public Health Service Commissioned Corps, he worked for 9 years in correctional medicine at a federal prison in Lexington Kentucky. He then changed agencies and spent 3 years in the FDA Office of Regulatory Affairs in the New England District Office. Later he transferred to FDA headquarters and has served for 6 years in the Office of Compliance at CDRH where he is currently still assigned. He is widowed with three grown children.

2Ted Lamson Ph.D.
Founder & Chief Technical Officer, NeoTract Interventional Urology | Teleflex

Ted Lamson, Ph.D. is Co-Founder and Chief Technical Officer of NeoTract, Inc., a wholly owned subsidiary of Teleflex, Inc. Ted is a primary inventor of the UroLift system for BPH and served as President and CEO of NeoTract for the first 4 years of the company and sat on its board of directors for the company’s entire history. He now oversees reimbursement and health policy, clinical affairs and medical affairs under Teleflex Interventional Urology. Ted sits on the board of directors for Eximis Surgical LLC and advises several other small medical device companies. He has over 25 years experience in the medical device industry in multiple fields and holds over 70 patents, many of which represent current commercial medical products. Ted has played a leadership role in other successful ventures, such as Vice President R&D for TransVascular, sold to Medtronic, co-inventor for Acclarent, sold to J&J, and Strategic Advisor to the ExploraMed incubator, which has launched several medical device companies including NeoTract, Inc. In addition to his deep start-up experience Ted has served as Vice President in the Vascular division of Medtronic and Section Manager within the prior-owned Schneider division of Pfizer. Ted held the position of Design Engineer for the Artificial Heart Program at Penn State University where he earned a MS and PhD in Biomedical Engineering. In 2011, Ted was awarded the Outstanding Engineering Alumnus award for Penn State, where he now serves on the curriculum advisory committee to the Biomedical Engineering department. Ted also holds a BS in Chemical Engineering from Rensselaer Polytechnic Institute.

2Christopher Letang
Managing Director, Professional Services, SRS Acquiom

Chris is the Managing Director of our Professional Services team. He has deep expertise in shareholder representation.  Chris and his team manage post-closing escrow claims, earnouts, purchase price adjustments and disputes. His team also manages the process by which post-closing merger proceeds are distributed to shareholders and other activities related to serving as shareholder representative.

Before joining SRS Acquiom, Chris practiced corporate law in the Colorado office of Cooley LLP, where he focused on venture capital transactions and mergers and acquisitions. He began his legal career at Cravath, Swaine & Moore LLP in New York City. At Cravath, he primarily represented underwriters in initial public offerings and high-yield debt offerings and lenders in commercial banking transactions.

Chris is a frequent contributor to M&A thought leadership via work on SRS Acquiom’s data studies, articles and speaking presentations. Chris holds a J.D. from Harvard Law School and a B.A. from Rice University.

2Stephen Levin
Managing Partner/Editor-in-Chief, Innovation in Medtech, LLC/MedTech Strategist

Prior to co-founding Innovation In Medtech, Stephen Levin served as Editor-in-Chief of Medical Devices for Elsevier Business Intelligence, where he directed the company’s editorial coverage of the medical device industry, following Elsevier’s acquisition of Windhover Information in 2008. This included managing the device content for the following publications: IN VIVO, START-UP, MEDTECH INSIGHT, The Gray Sheet, and The Silver Sheet, along with the In3 medical device partnering conference series. Stephen joined Windhover Information in 1997, whereas Executive Editor, he specialized in covering the device industry, distribution, and legal issues. He also served as the company’s General Counsel. He also formerly was an Editor of Health Industry Today, a leading publication in the health care industry.

Prior to joining Windhover, Stephen was Senior Counsel to the US Senate Permanent Subcommittee on Investigations, where he directed Senate investigations into a wide variety of areas including health care fraud and abuse, international organized crime, and corruption in federal contracting programs, while also participating in other Senate investigations including the Whitewater inquiry. Before joining the Subcommittee, he was with the Federal Election Commission (enforcement and regulatory counsel) and the Department of Justice (international criminal law).

2Scott Lovald
Managing Engineer/Biomedical Engineering, Exponent

Dr. Lovald specializes in design evaluation, performance optimization, and failure analysis of medical devices, mechanical systems, and structural materials. He provides scientific and engineering consultation to clients with challenges in orthopedic, cardiovascular, pharmaceutical, ophthalmologic, tissue reconstruction, and dental applications. He has particular expertise evaluating the performance of devices with computational modeling and cadaveric experimentation, and often focuses this expertise towards issues concerning the regulatory compliance, product liability, and clinical performance. In addition Dr. Lovald has assisted clients in developing and conducting pre-clinical device testing programs (e.g ASTM, ISO), device risk analyses, product safety evaluations, intellectual property assessments, health economics analyses, characterization of biomaterials, and determination host tissue material properties.

Dr. Lovald has many research interests which span theoretical, engineering, and clinical topics. He has published work on the design and optimization of bone fracture internal fixation devices, the evaluation of local tissue flaps, bioabsorbable and PEEK polymers for new orthopaedic applications, investigation of ophthalmologic mechanics during tonometry, hemodynamics and local mechanics of diseased arteries and aneurysms, evaluation of analgesic outcomes after orthopedic surgery, as well as a number of health and economics studies from national healthcare databases. He recently coauthored the textbook Orthopaedic Biomaterials in Research and Practice, 2nd Ed., which was published in 2014.

Immediately prior to working at Exponent, Dr. Lovald cofounded a company where he initiated and directed the research, seed funding, design, manufacturing, FDA 510(k) clearance, intellectual property strategy, and post-market study Investigational Review Board approval of a patented mandibular fracture fixation system. He has also worked in the area of clinical research by designing and managing post-market studies which investigated the clinical outcomes of total knee arthroplasty, total hip arthroplasty, atrial fibrillation, knee resurfacing, and spinal degenerative disc disease patients.

2Hongbo Lu
Partner, Lilly Asia Ventures

Dr. Hongbo Lu is a partner at Lilly Asia Ventures, a healthcare-focused investment firm with over USD$1.2 billion AUM. Previously, Dr. Lu was with OrbiMed Advisors, serving as its Managing Director in Asia, responsible for over $500m public equity investment portfolio in emerging markets, as well as led a few private equity investments and served as board of directors of private and public companies.

Dr. Lu has over 15 years of investment and operational experience in healthcare industry, including her tenures at OrbiMed, Piper Jaffray & Co. and life science start-up Zyomyx. Dr. Lu received a Ph.D. in BioEngineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and graduated with honor from Tsinghua University in China.

2Patrick Maguire, MD, PhD, MBA
President and Director, CyberHeart Incorporated

Dr. Maguire is President and Director of CyberHeart Incorporated, Mountain View, California, a medical device company focusing on a non-invasive approach to ablate cardiovascular tissue, with an eye toward the treatment of cardiac arrhythmias. CyberHeart has raised $17M in equity capital to date.  The Company is raising a Series B and intends to use the funds for additional clinical trials leading toward approvals and commercialization.  Dr. Maguire is responsible for all operations and spearheading the strategic direction of the company.

Dr. Maguire joined CyberHeart Inc. in 2008-9 following the successful acquisition of the oncology assets of Targent Incorporated, a specialty pharmaceutical company , located in Princeton, New Jersey.  He served as President, CEO, and Director there from 2002 to 2006.  Dr. Maguire oversaw the in-licensing of three compounds and the out-licensing of another, prior to the successful acquisition of the company.  Targent’s late-staged oncology asset received NDA approval. The drug asset “Fusilev” has generated in excess of $1B in sales revenue since launch.

Prior to joining Targent, Dr. Maguire was Vice President of Medical Affairs and Technology Development at VitaGen Incorporated, acknowledged as a leader in the development of a bio-artificial liver device, employing extracorporeal cellular therapy for liver disease.  He has overseen the preparation of IND’s, NDA’s, and IDE’s.  Dr. Maguire managed VitaGen’s clinical trials in acute and chronic liver failure as well as medical and industry collaborations.  He was an integral participant in financing rounds that secured new investors in the United States and Asia.  He holds over a dozen patents.

Dr. Maguire served on the Board of Directors and Executive Chairman of New Cardio Inc., Sunnyvale, California, (“NWCI”.OTC BB) and previously served on the Board of HemolifeMedical Incorporated, San Clemente, California.  He has served as Chairman of the Board, Chair of the Governance Committee and as an Audit Committee Member.

He is a Cardiovascular and Thoracic surgeon and has acted as a principal investigator for devices and associated clinical trials.   He is a fellow of the American and Royal College of Surgeons and a member of over twenty medical, academic and business societies.  Dr. Maguire holds MD and PhD (Physiology and Biophysics) degrees from Georgetown University.  He completed additional course work in Hematology at the University of Oxford.  He has published in the fields of cancer, collagen production and liver cellular support.  Dr. Maguire received an MBA degree from Pepperdine University, and he earned his AB degree from Wesleyan University.  He completed surgical and cardiovascular fellowships at The Peter Bent Brigham Hospital, Harvard University, Stanford University, and The Royal Brompton and Harefield Hospitals, Imperial College, London, UK.

2Josh Makower
General Partner, New Enterprise Associates

Josh has worked closely with NEA since his time as an EIR back in 1995 and joined full-time as a General Partner on NEA’s healthcare team leading our medtech/healthtech practice in 2015. Josh is also the Founder and Executive Chairman of ExploraMed, a medical device incubator that has created 8 companies over the past 20 years. Notable transactions from the ExploraMed portfolio include Acclarent, acquired by J&J in 2009. EndoMatrix, acquired by C.R. Bard in 1997, TransVascular, acquired by Medtronic in 2003 and Neotract acquired by Teleflex in 2017.  On-going ExploraMed/NEA ventures include Moximed, Willow and ExploraMed V.  In addition to his role at NEA, Josh serves on the faculty of the Stanford University Medical School as an Adjunct Professor of Medicine and is Co-Founder of Stanford’s Biodesign Innovation Program.  Josh currently serves on the board of directors for DOTS Technology Corp., Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, SetPoint Medical, Willow and Coravin.  Josh holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women’s health, and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor’s degree in Mechanical Engineering from MIT. Josh is also a member of the College of Fellows of the American Institute of Biomedical Engineering.

2Juan-Pablo Mas
Partner, Action Potential Venture Capital

Juan-Pablo is a partner at Action Potential Venture Capital in Palo Alto, CA, and invests in companies that are pioneering bioelectronic medicines.  Juan-Pablo is a Board member of Saluda Medical, SetPoint Medical, Neuspera Medical, Cala Health, CVRx, and Presidio Medical.  He was previously an investor at Morgenthaler Ventures and Lightstone Ventures, where he focused on therapeutic medical devices, digital health, and biopharmaceutical investments.  There he served as a Board observer at Ardian (acquired by Medtronic), Twelve (acquired by Medtronic), Holaira, Cabochon Aesthetics (acquired by Ulthera/Merz), and Miramar Labs.

Prior to investing, Juan-Pablo led efforts in R&D and Strategy in Medtronic’s CardioVascular Division, including Pipeline Strategy, White-Space expansion, Business Development, and M&A integration efforts.  He was named “Medtronic Inventor of The Year” in 2008, and has 30+ patents, granted or pending. Subsequently, he served on the Global brand Strategy team at Eli Lilly within the Cardiovascular business.

Juan-Pablo earned an MBA from Stanford Graduate School of Business.  He conducted research in the Neuroscience Department, and in the Neurology Department at Stanford Hospital, while completing an M.S. in Electrical Engineering at Stanford University.   He received his B.S. in Electrical Engineering from the University of Massachusetts, Amherst.

Juan-Pablo currently serves on the Board of Directors of the Boston-based non-profit, InnerCity Weightlifting, where the gym is used to replace segregation and isolation with economic mobility and social inclusion, disrupting the system that leads to urban street violence.

2Scott McCall
Partner, Wilson Sonsini Goodrich & Rosati

Scott McCall is a partner in Wilson Sonsini Goodrich Rosati’s employee benefits and compensation practice. He represents both private and public technology clients in connection with executive compensation and employee benefits matters. Scott’s practice focuses on the design and implementation of equity compensation and bonus plans, executive employment agreements and the corresponding tax, accounting, and securities law issues. He also is actively involved with the firm’s transactional practice, working with employers to manage the transition of employees and their benefits during and after a merger or acquisition, joint venture, or spin-off.

2Casey McGlynn
Partner, Wilson Sonsini Goodrich & Rosati

In 1990, Casey McGlynn formed the Life Sciences Group at Wilson Sonsini Goodrich and Rosati, a nationally recognized leader in the representation of startup and emerging growth companies in the life sciences field. Casey has one of the largest practices in the country focused on Medtech, Mobile Health and Biotech companies.

Casey has formed, represented, sold and taken public many of the most important medical device companies started during the last 25 years.

Casey has extensive hands on experience in helping entrepreneurs form, build, fund and sell their companies. He has formed, participated with the boards of and invested in companies in all of the major Medical Device fields. Over the last 25 years he has built close working relationships with an unparalleled list of entrepreneurs, doctors, investors, engineers, and managers in this industry. Through his portfolio of companies he has met with and negotiated with the leaders of all of the major Medtech acquirers.

Over much of his career, Casey participated in forming and managing several small funds all of which have been top quartile performers. In 2005, Casey founded Life Science Angels, an angel organization focused on investing in biotechnology and medical device companies. Since formation, LSA has invested over $30 million in more than 40 companies which have received an additional $600+ million in follow-on funding from VCs.

Casey is a member of the board of directors of the Fogarty Institute for Innovation, the Medical Device Manufacturers Association and was a founding board member of the Emerging Business Committee of BIO.

2Vance B. Moore
President, Business Integration, Mercy Virtual

Vance B. Moore serves as President, Mercy Virtual – Business Integration. He co-leads Mercy Virtual with Dr. Gavin Helton, who leads clinical integration.

Moore’s career has included operational and sales roles in health care consulting, distribution, manufacturing, third party logistics and provider operations. Moore joined Mercy in 2002 as part of Resource Optimization & Innovation (ROi), Mercy’s supply chain division and one of the world’s top health care supply chain operations, serving in a variety of roles including president and CEO. In 2011, he was named senior vice president of operations for Mercy, and in 2016 president, business integration. He expanded this role to include his leadership of Mercy Virtual in March 2018.

Prior to Mercy, Moore served for 17 years with Baxter/Allegiance, Cardinal Health and the health care division of the UPS Logistics Group.

Today, Moore is responsible for all operational aspects of the Mercy Virtual business unit. He is also board chair for ROi and has corporate oversight responsibilities for Mercy Technology Services (MTS), Procedural Services and Mercy Research. Moore is on the governing committee of the National Evaluation System for health Technology (NESTcc) and is a board member of Omnicell Incorporated (NASDAQ: OMCL) and Ascension Ventures. He is a former board member of the Strategic Marketplace Initiative (SMI) and The Bellwether League. Additionally, Moore was recognized as SCM World’s 2015 “visionary of the year.”

Moore has a bachelor’s degree in industrial management from the University of Arkansas.

2Jack Moorman
Chairman, US-Japan MedTech Frontiers (USJMF)

Jack Moorman is a Partner in Nichibei MedTech Advisors and the Principal at LeVaunt, LLC. Both are consulting firms providing advisory services to companies and organizations, particularly early stage ventures in the fields of healthcare and wellness consumer products. He was also honored to be named Visiting Faculty Member, Graduate School of Medicine, Osaka University.

Jack is also Chairman of US-Japan Medtech Frontiers, a nonprofit organization. US-Japan Medtech Frontiers organizes conferences and symposia in Japan to promote collaboration between the US and Japan to create and commercialize novel medical devices. Now in its Fifth year, USJMF has organized conferences in Sendai, Osaka, Hiroshima, Okinawa and in 2018 the conference will be in Shizuoka City. In addition, each year USJMF has organized a symposium for Japanese senior executives held in Tokyo with the support of the US Embassy and other organizations. USJMF is also a strong supporter of the Japan Biodesign Program, now in its third year.

Jack has been involved in a wide array of companies, technology, and products. In addition to a turn-arounds and serial entrepreneurship, he has held Board membership at one of the largest U.S. providers of skilled nursing and assisted living, and consulted with: a Russian investment group on fiber lasers; a Chinese company supplying polyurethane materials; a ski equipment company; a company supplying consumer products to big box stores; Japanese companies looking for medical device acquisitions; and orthopedics robotic companies. More recently he has been assisting Japanese companies in developing innovative medical devices and serves on the Boards of two early stage medical device companies and advises others. To date, he has fourteen issued U.S. patents.

2Susan Morano
Vice President, Business Development, Johnson & Johnson Medical Devices

As Vice President of New Business Development and a member of the Medical Devices & Diagnostics Group Operating Committee, Susan has responsibility for strategic planning and licensing & acquisitions for the Medical Devices & Diagnostics Group.

Susan joined Johnson & Johnson as a college recruit in the finance organization. During her tenure in the Corporation, she transitioned through a number of positions with increasing responsibility through six operating companies, primarily within finance and new business development. Susan has been involved in a number of significant transactions within MD&D.

Ms. Morano received her BS in accounting from Villanova University and an MBA from Columbia University.

2Bali Muralidhar
Partner, MVM Partners, LLP

Bali joined MVM in 2012. Before joining he was a key member of Bain Capital’s healthcare deal team. Prior to that he was a management consultant in Bain & Company’s healthcare team. Bali obtained a degree in Clinical Medicine from Oxford University and practiced general surgery at the John Radcliffe and Addenbrooke’s Hospitals. He has a PhD in translational cancer research from the MRC Cancer Cell Unit, Cambridge University, and has published over a dozen peer reviewed papers.

Bali is a member of the boards of Onbone Oy, Wilson Therapeutics AB, Valneva SE and Zipline Medical, Inc. and is an observer on the supervisory board of Providence Medical Technology, Inc.

2Scott Murano
Partner, Wilson Sonsini Goodrich & Rosati

Scott Murano is a corporate and securities partner in Wilson Sonsini Goodrich & Rosati’s Palo Alto office. Scott advises companies on general corporate matters, including formation and operation, corporate governance, intellectual property and licensing, and employment-related matters. He also has assisted companies in numerous capital raising transactions, including early- and later-stage venture capital financings, debt financings, and public offerings. In addition, Scott advises companies on transactional matters and has worked on a number of merger and acquisition transactions, including public and private company mergers and acquisitions and joint ventures. Scott’s experience with venture capital financings and public offerings includes representation of venture capital firms.

2Philip Oettinger
Partner, Wilson Sonsini Goodrich & Rosati

Philip Oettinger is a partner in the life sciences practice at Wilson Sonsini Goodrich & Rosati, where he focuses primarily on medical device, biotechnology, pharmaceutical, diagnostic, and digital health companies. His practice involves assisting private and public companies with corporate governance, initial public offerings, mergers and acquisitions, public company reporting, and private equity and debt financings. He routinely works with incubators on structuring matters and balancing their rights with those of the companies they are forming. Philip serves as co-chair of the Finance Committee and a member of the Compensation Committee.

From 1995 until 2000, Philip was with the Securities and Exchange Commission in Washington, D.C., where he inspected stock exchanges, worked on corporate finance matters, led enforcement investigations, and served as special counsel to Commissioner Laura S. Unger.

2Steve Parmelee
Of Counsel, Wilson Sonsini Goodrich & Rosati

Steve Parmelee is Of Counsel in Wilson Sonsini Goodrich & Rosati’s Seattle office. He has over 25 years of experience in inter partes proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (PTO). He has represented patent applicants in many patent interference proceedings at the PTAB. In addition, he has experience representing clients in the new post-grant trial proceedings that were enacted in the America Invents Act of 2011, including inter partes review (IPR) and covered business method (CBM) challenges to issued patents.

Steve has acted as lead counsel in a number of patent interferences at the PTAB covering a wide range of technologies, including medical devices, photolithography, wireless security protocols, high-density recording media, and biotechnology. Notable cases include University of Washington v. Eli Lilly & Co., in which Steve represented the prevailing party in establishing the now-standard “”two-way test”” for declaring interferences, and Affymetrix v. Incyte, where he represented the prevailing party Affymetrix in a major gene array dispute.

Steve’s prior experience includes positions as in-house patent counsel for a pioneering Seattle technology company and for a multinational pharmaceutical company. These roles provided him with an understanding of the pressures and expectations of corporate counsel, which allows him to work successfully with a variety of companies and institutions. Prior to joining Wilson Sonsini Goodrich & Rosati, Steve was a partner at a national intellectual property law firm, founding its Seattle office in 1990 and serving as its managing partner through 2008.

2Jenell Paul-Robinson
MSN, RN, Vice President, Clinical Value and Provider Relations, MedTech Innovator

Jenell Paul-Robinson, MSN, RN is Vice President, Clinical Value and Provider Relations at MedTech Innovator. She received her master’s degree in Nursing Administration from UCLA.

Jenell brings over 20 years clinical, operational, and administrative expertise to the MedTech Innovator team. Her specialties include critical care nursing, strategic sourcing, and hospital organization value analysis experience. Prior to joining MedTech Innovator, Jenell served as the value analysis coordinator for UCLA Health. Jenell served on several national supply chain and academic medical center value analysis professional committees, charged with evaluating emerging technologies and supply chain initiatives for GPO member consideration.

2Donna Petkanics
Partner, Wilson Sonsini Goodrich & Rosati

Donna Petkanics is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. Her law practice focuses on the representation of growth companies, with a particular emphasis on corporate and securities issues. She represents both privately held and public companies across a broad range of industries, including telecommunications, Internet infrastructure, networking, life sciences, computer software and hardware, clean technology and energy, and electronics. She has experience representing companies in many types of corporate transactions, including mergers and acquisitions, initial public offerings, and joint ventures. She also counsels clients who are starting new businesses with respect to general corporate matters and protection of their intellectual property.

During her tenure at the firm, Donna has served in a number of management positions, including managing director of operations and chair of the Operations Committee from 2000 to 2006; member of the firm’s board of directors and Policy Committee; chair of the Compensation Committee; associate managing partner of the firm; and co-chair of the Hiring Committee and Nominating Committee. She served on the board of directors of the Wilson Sonsini Goodrich & Rosati Foundation from 2000 to 2010.

Prior to attending law school, Donna was a staff economist in the Executive Office of the President during Jimmy Carter’s administration and also worked for the House of Representatives. She began practicing at Wilson Sonsini Goodrich & Rosati in 1985.

2Ari Raval
Managing Director, Perella Weinberg Partners

Mr. Raval is a Managing Director in Perella Weinberg Partners’ Advisory business. He focuses on advising clients in the Healthcare industry.

Mr. Raval has more than 12 years of investment banking experience assisting companies on a wide range of strategic matters. During his tenure at Perella Weinberg Partners, he has advised a number of clients including Cardinal Health on its acquisition of Medtronic’s Patient Recovery business; HeartWare on its sale to Medtronic; Wright Medical on its merger with Tornier; CareFusion on its sale to BD; Medtronic on its acquisition of Covidien; and Novocure and Penumbra on their IPOs.

Prior to joining Perella Weinberg Partners in October of 2012, Mr. Raval was at J.P.Morgan from 2005 to 2012, where he most recently served as an Executive Director responsible for advising a broad range of Healthcare clients on M&A and capital raising transactions. He was previously a Product Manager at Pinnacor. Mr. Raval began his career as a Business Analyst at Mitchell Madison Group.

Mr. Raval earned a Bachelor of Arts in Economics and the Biological Basis of Behavior from the University of Pennsylvania and a Masters of Business Administration from the Wharton School at the University of Pennsylvania.


2Ulrico Rosales
Partner, Wilson Sonsini Goodrich & Rosati

A partner in the employment law practice at Wilson Sonsini Goodrich & Rosati, Ulrico (Rico) Rosales has practiced employment law for more than 20 years—17 of them in Silicon Valley—and has seen virtually every type of employment issue faced by technology and growth companies. Rico’s practice encompasses all aspects of employment law, including counseling and representing clients in litigation matters.

Rico has represented clients in several jury and non-jury trials, including discrimination, wrongful termination, and class action matters. He has successfully tried numerous discrimination cases, including race, sex, age, and disability cases. His trial experience also includes successfully defending cases against the Equal Employment Opportunity Commission (EEOC) and the Office of Federal Contract Compliance Programs (OFCCP). Rico also routinely handles litigation matters involving wrongful termination, sexual harassment, constructive discharge, breach of contract, wage and hour and fraud.

Rico draws on his extensive litigation practice when counseling clients. On a daily basis, he consults with human resources professionals, executives, and board members regarding all aspects of the employment relationship. These issues include preventive personnel practices, employee terminations, workplace investigations (including those involving sexual harassment), wage and hour matters, independent contractor audits, and reductions in force. He also advises companies regarding employment due-diligence matters in the merger and acquisition context. In addition to the scores of clients Rico represents in the technology field, he frequently advises venture capital firms on employment matters and also is called upon to advise the management teams of companies being acquired by other companies.

A significant portion of Rico’s practice involves advising companies on employee mobility and trade secret misappropriation issues, including the interpretation and enforceability of non-compete agreements, employee raiding and solicitation matters, and counseling clients as to preventive measures designed to minimize the risks associated with hiring competitors’ employees or having employees depart to work with competitors. Rico has counseled more than 150 technology companies dealing with such issues and has represented companies in approximately 25 court actions involving these matters. For example, he represented broadcom in GlobeSpan v. O’Neil, which resulted in a California federal court decision declaring that the inevitable disclosure doctrine is not the law of the state.

Rico is a frequent speaker on employment matters. He has also commented for numerous publications, including the Los Angeles Times, the San Jose Mercury News, Business Week, and legal-profession newspapers. Since 2001, San Jose Magazine has identified him as one of Silicon Valley’s best employment lawyers. In addition, he provides pro bono legal services to several Bay Area nonprofit organizations.

Rico is a former co-chair of the firm’s Nominating Committee and a former member of the Policy Committee.

Rico is a former law clerk to the Honorable Zita L. Weinshenk of the U.S. District Court for the District of Colorado. More recently, he was the managing partner of the Palo Alto office of McCutchen, Doyle, brown & Enersen.

In addition to English, Rico is proficient in Spanish.

2Renee Compton Ryan
Vice President, Venture Investments, Johnson & Johnson Innovation – JJDC, Inc. (JJDC)

Renee Ryan, Vice President, Venture Investments, joined Johnson & Johnson Innovation – JJDC, Inc. (JJDC) in 2011. She is based in Silicon Valley, California and primarily supports the strategic investment activities in medical devices.

Mrs. Ryan’s background includes over 15 years of healthcare investment banking. Most recently, she ran the medical device investment banking effort at R.W. Baird & Co. Previously, she lead the West Coast healthcare group at Jefferies & Co. and was in the healthcare investment banking groups at Goldman Sachs and Credit Suisse.

Mrs. Ryan received an MBA from Columbia Business School and a Bachelor’s degree from Georgetown University.  She was nominated for the Silicon Valley Business Journal “Women of Influence” in 2011 and participated in the Smith Tuck Global Leaders for Women Program in 2014.  She recently was nominated to the Fierce Medical Devices Top Women in Medical Devices 2015 list.

2Vahid Saadat
CEO, Arrinex, Inc.

Vahid Saadat is a serial medical device entrepreneur with 25 years of experience. Vahid currently runs Arrinex, Inc., a company developing a one time, office based therapy for chronic rhinitis. Prior to Arrinex, Vahid served as the CEO of Voyage Medical, funded by Kleiner Perkins, Three Arch , RWI and Abbott Ventures. Voyage Medical developed treatments for atrial fibrillation. The Direct Endocardial Visualization Ablation Catheter – IRIS™ System provides physicians a real-time high-resolution color view of inside the heart utilizing a micro CMOS camera. The patented direct endocardial visualization and ablation catheter – IRIS™ System provides the clinician a direct view of the targets and delivers the therapy in a predictable fashion. Voyage medical was integrated into Intuitive Surgical. Prior to Voyage Medical, Vahid co-founded Baxano, funded by Prospect ventures, Three Arch Partners and Kearney Ventures. Baxano is a spinal stenosis treatment company that recently merged with Trans1, inc. Prior to Baxano, Vahid co-founded USGI medical, funded by Interwest partners, JJDC, and Alta Partners. USGI Medical is a commercial stage company specializing in the treatment of diseases through the natural passageways of the body. Operating through the body’s natural orifices offers promise for less pain, shorter hospital stays, reduced risk of wound infection and no external scars – and is rapidly becoming an option demanded by patients and healthcare providers. USGI offers surgeons and gastroenterologists the tools they need to offer millions of potential patients a less invasive surgical option. Prior to USGI, Mr. Saadat started AngioTrax, Funded by Onset Ventures, Delphi Ventures and IVP Capital. AngioTrax developed a technology for the treatment of end stage cardiac patients. Mr. Saadat holds a Bachelor’s and Master’s degrees in engineering from the University of Texas at Austin. He is named an inventor on 200 patents in a variety of medical specialties.

2Siddarth Satish
Founder and CEO, Gauss Surgical, Inc.

Siddarth Satish is the Founder and CEO of Gauss Surgical, a medical technology company using computer vision and machine learning to make surgery and childbirth safer and more cost-effective. Gauss’s first application, Triton, uses the iPad to monitor blood loss from digital images of sponges and canisters, with the goal of improving obstetrical safety, reducing unnecessary transfusion, and preventing retained sponges. In his operating role, Siddarth has led the team through seven US/EU regulatory clearances (including FDA De Novo approval and raised $40 million in venture capital. Siddarth previously served as an Entrepreneur-in-Residence at StartX, Stanford University’s Startup Accelerator, and as a SIMdesign Fellow in the Department of Surgery at Stanford. Siddarth was born in India and immigrated to the United States at the age of 7. He holds a B.S. in Chemical Engineering from the University of California, Berkeley, and an M.S. in Bioengineering from the UCSF/UC Berkeley Joint Graduate Group in Bioengineering. He serves on the Technology Committee of the Anesthesia Patient Safety Foundation, and was named to the Forbes 30 Under 30 list in healthcare.

2Elton Satusky
Partner, Wilson Sonsini Goodrich & Rosati

Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. He specializes in public and private corporate finance and corporate law and governance. Elton also has considerable expertise in the areas of mergers and acquisitions and venture capital.

2Peter Shagory
Executive Vice President, Strategy and Corporate Development, CONMED Corporation

Peter Shagory joined CONMED Corporation as Executive Vice President, Strategy and Corporate Development in May 2015. Mr. Shagory has more than 20 years of experience in healthcare venture investing and mergers and acquisitions through his previous venture capital, investment banking and corporate roles. Prior to joining CONMED, Mr. Shagory led the strategy and business development efforts for Cardinal Health’s Medical Products Group within the Medical Segment from June 2013 to May 2015, where he played a key role in Cardinal Health’s entry into the interventional cardiovascular and the advanced wound care categories. Prior to that, Mr. Shagory led the healthcare and life sciences investment effort at Baird Venture Partners from January 2004 to mid-2013, focusing on medical technology and research tools and diagnostics. Mr. Shagory earned an MBA from Dartmouth’s Tuck School of Business and a BS in Finance from Miami University in Oxford, Ohio.

2Bernard Shay
General Counsel, Earlens Corporation

Bernard Shay joined Earlens as General Counsel in June 2015. Bernie is a veteran medical technology expert with over 25 years of experience with M&A, litigation, licensing, intellectual property, compliance, business development and engineering at a range of leading companies, including Miramar Labs, Johnson & Johnson, General Electric and IBM. Mr. Shay holds a BSEE and MSEE from Virginia Polytechnic Institute and a JD, cum laude from Pace University.

2Ryan Siskey
Principal and Office Director, Exponent

Mr. Siskey specializes in applying experimental methods to assist in the product development process. While his focus has been on medical device development projects, he also consults on material selection, consumer products and consumer electronics. As the supervisor of the ISO 17025 accredited ISO (A2LA Certificate 2561.01) medical device testing laboratory in Exponent’s Philadelphia office, he has a strong foundation in the quality system requirements for medical device development. Additionally, as a certified lead ISO 13485 auditor, he is able to bridge his experimental background and the regulatory and compliance issues that manufacturer’s routinely face.

Mr. Siskey’s has extensive experience in performing wear and material testing in accordance with ASTM and ISO standards, conducting cadaveric testing, and developing customized protocols. This includes analyzing and testing devices from feasibility through post market surveillance and helping to obtain regulatory approval for their devices. His experience includes materials characterization, complete device evaluation, and a firm understanding of the device tissue interface including coatings characterization. Mr. Siskey also has experience in failure analysis of devices that has been used to help client’s conduct root cause investigations of their devices and respond to FDA deficiency letters. While standardized testing plays a key role in characterizing most devices, new devices and new questions about existing products makes custom protocols a necessity in the lab. Mr. Siskey has experience with developing these protocols for devices and products, from Class I to Class III.

Mr. Siskey received his MTS certification, which enables him to develop customized testing procedures on the laboratory servo-hydraulic load frames and spine wear simulator. He also maintains an understanding of mechanical testing using a wide variety of testing equipment. Additional methods include surface characterization using a Zygo white light interferometer, and chemical characterization using FTIR. Previous experience in tribology has included re-design of a Matco hip wear tester, re-design of a biaxial knee wear tester, and design of a spine disc wear tester. Mr. Siskey has also developed procedures for devices including syringes, luer fittings, needles, and catheters.

Additionally, Mr. Siskey has conducted environmental monitoring with Exponent’s Environmental Sciences group. Specifically he has set up, maintained, and calibrated air particulate monitoring equipment and weather monitoring equipment. He has also conducted analysis of the data collected with these systems.

2Brian Smith
Co-Founder and CEO of RedCrow, Inc.

Brian A. Smith is the Co-Founder and CEO of RedCrow™ Inc. an equity niche-funding platform presenting professionally vetted investment opportunities in innovative healthcare startups to an accredited crowd of investors. Backing a vision with social impact is at the heart of RedCrowTM investing.

Prior to RedCrowTM Brian was a Financial Advisor with Morgan Stanley Smith Barney, advising high net worth families. During that time he and his wife experienced the tragic loss of their first child 24 weeks into the pregnancy. It was at that pivotal moment when Brian decided to channel his investment career into meaningful work helping other families who experience complicated pregnancies. Brian left Morgan Stanley and adopted an active role in MindChild Medical, a pioneer in the development of non-invasive fetal heart monitoring. This experience and the writing of the 2012 JOBS Act had Brian began to envision a day when crowdfunding would evolve into an equity based model vs donation based . So in 2015, alongside Jerry Harrison, Brian founded RedCrow™ with a mission to democratize the investment process for people otherwise shut out of early-stage investing opportunities. He resides in Mill Valley, CA with his wife and two daughters.


2Mark Speers
Partner and Managing Director, Health Advances, LLC

Mark has been advising senior medtech executives for 36 years. He co-founded Health Advances in 1992 after gaining ten years of strategy consulting experience in the healthcare industry as a Partner at Bain & Company, an international management consulting firm.

At Health Advances, Mark works extensively with clients to evaluate the commercial potential and develop market launch strategies for new medical devices and diagnostics. He also offers expertise in mergers and acquisitions work for strategic and financial buyers, having now contributed to over $80 billion in client transactions. He served on the Board of Directors of MassMEDIC for six years. Mark is a strong advocate for the industry through his work with AdvaMed and MDMA as well as frequent speaking engagements and publications.

Mark graduated magna cum laude from Dartmouth College with a degree in engineering and was elected Phi Beta Kappa. He earned his MBA from the Stanford Graduate School of Business where he was honored as an Arjay Miller Scholar.

2Nicole Stafford
Partner, Wilson Sonsini Goodrich & Rosati

Nicole Stafford is a partner in the firm’s Austin office, where she specializes in patent litigation with an emphasis on pharmaceutical and life sciences litigation. She has successfully represented clients in bench and jury trials in district courts across the country, appeals to the U.S. Court of Appeals for the Federal Circuit, and hearings before the International Trade Commission, including as lead litigation counsel.

Nicole also has successfully represented prominent generic pharmaceutical companies in Hatch-Waxman litigation at both the trial and appellate levels, including several recent successful bench trials in the District of Delaware and a Federal Circuit appeal. She has represented a variety of pharmaceutical and life sciences clients in litigation and appellate matters, including Par Pharmaceutical, Inc.; Paddock Laboratories, Inc.; Mylan, Inc.; Synthon IP, Inc.; Eppendorf Corp.; Ventana Medical Systems Amgen Inc.; Bausch & Lomb, Inc.; Perlegen Sciences, Inc.; Gencell SAS; Bayer AG; DeKalb Genetics Corp.; and Monsanto.

Nicole is a former National Science Foundation Doctoral Fellow with M.S. and Ph.D. degrees in chemistry. She has authored numerous peer-reviewed technical articles and conducted research in polymer and organic chemistry, organometallic catalysis, synthetic inorganic and bioinorganic chemistry, neuropharmacology, and genetics. Her strong technical background has allowed her to effectively represent clients in a wide range of technological areas, including pharmaceuticals, ophthalmics, controlled release technologies, biologics, biomedical devices, DNA chips and microarrays, angiogenesis, immunohistochemical staining/antigen retrieval, genetically engineered plants, insecticides, polymers, petrochemicals, semiconductors, and computer-related applications and devices.

2Jody K. Thelander
Founder & CEO, J.Thelander Consulting

Jody is a compensation executive with a track record of successful results and nearly two decades of professional experience. Jody has a keen understanding of business realities through a diversified background in compensation, sales and customer service. Her surveys and resulting reports have become a well-respected and highly desired tool for compensation decision-makers in the private business sector. J.Thelander Consulting provides board and compensation consulting to a full range of businesses, from emerging growth companies, including life sciences and technology, to Fortune 500 businesses.  Jody also runs the Thelander Private Company Compensation Survey as well as the Thelander-PitchBook Investment Firm Survey.  She works closely with venture capital, private equity and law firms, providing compensation strategies for portfolio companies and clients.

2Meg Thering
Associate, Wilson Sonsini Goodrich & Rosati

Meg Thering is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on employment litigation. Meg has extensive experience representing employers in both single-plaintiff and class and collective action litigation. Among other labor and employment matters, she represents employers in federal and state court litigation and before administrative agencies in matters involving trade secrets, employee misclassification and other wage and hour issues, ERISA, discrimination, harassment, retaliation, the Family and Medical Leave Act, and unemployment insurance. In ERISA and trade secrets matters, she has experience representing employers on both the defense and plaintiff side.

Meg also has experience counseling employers on issues such as worker classification, trade secrets and employee mobility, covenants not to compete, hiring practices, employment policies, employment contracts, terminations and reductions in force, internal investigations, leave laws, and numerous other issues that arise under federal, state, or local labor and employment laws. She has reviewed and drafted numerous employment policies, including employee handbooks, vacation policies, and family and medical leave policies. In addition, Meg has considerable merger and acquisition experience, assisting clients in structuring corporate transactions to minimize employment-related risks and maximize the value of the transaction from an employment perspective.

Meg also devotes a significant portion of her practice to pro bono work with the Safe Passage Project and Community Legal Services of East Palo Alto, representing unaccompanied minors who have immigrated to the U.S. in immigration and family court.

Prior to joining the firm, Meg worked in the employment litigation group in the New York City office of Epstein Becker & Green, P.C. Before that, she worked at Skadden, Arps, Slate, Meagher & Flom LLP in Los Angeles.

2Fred Toney 
CEO and Co-Founder, Launchpad Digital Health

Fred founded Launchpad Digital Health in 2013. He spent 20+ years in the technology, medical and digital health markets: Co-Founder, Executive Chairman and CFO of RxList (sold to WebMD); CEO of HealthCentral at its sale and CFO at its IPO on Nasdaq; EVP & CFO of C8 MediSensors which received regulatory approvals of its medical device + medical software application in 27 EU countries. 15+ years in research, investment banking, portfolio management with 100+ companies funded or sold. Current BOD positions include Limelight Health, Hint Health, LifeDojo, Tueo Health, Moving Analytics, Stop, breathe & Think, Wellstart Health and others.

2Rafael Torres
Senior Vice President, Business Development and Strategy, Varian Medical Systems

Rafael Torres joined Varian in May 2015, as senior vice president for business development and strategy.  In this role, he leads the company’s strategic plans for growth through acquisitions, investments, and partnerships that complement our current portfolio of businesses. Prior to joining Varian, Mr. Torres, served as global head of healthcare for GE Ventures and GE Equity, where he built a strategic investments portfolio of over 30 healthcare companies.  He was a founding member of GE Ventures and a member of its senior leadership committee.  Mr. Torres led the healthcare investment team, and represented GE on portfolio company boards, including CardioDx, InSightec, LipoScience, Navinet and ParadigmHealth.

Mr. Torres was a judge of the healthymagination Cancer Innovation Challenge and a member of the StartupHealth transformers advisory panel.  He has been featured in healthcare publications and conferences including The Gray Sheet, MedDevice Daily, SXSW, Slush Digital Health and Biomed Israel. Previous to that, he worked for The Boston Consulting Group and Citibank N.A.  He holds an MBA degree from Harvard Business School and a B.A. in economics from the Universidad del Pacifico in Lima, Peru.

2Takahiro “Taka” Uchida
Founder & CEO, Japanese Organization for Medical Device Development, Inc. (JOMDD)

• Board Certified physician in Internal medicine and Cardiology
• Founder and CEO of JOMDD, Inc. (Tokyo, Japan), the Japanese first medical device incubator (2012- current)
• Founder and CEO of Necess Medical, LLC, a Silicon Valley-based consulting firm for start-up medical device companies (2011-2013)
• General Management Program from Harvard Business School (2010)
• Medical Director at Boston Scientific Corporation (2007-2011)
• The first Japanese Medical Officer/Reviewer at the Center for Devices and Radiological Health, U.S. FDA (2005-2007)
• COO at the Center for Clinical Trials of Japanese Medical Association (2003-2005)
• Fellow at Harvard Clinical Research Institute/Harvard Medical School (2002-2003)
• M.S. in Epidemiology from Harvard School of Public Health (2002)

2Kwame Ulmer
Principal, Ulmer Ventures

Kwame Ulmer is a MedTech executive with nearly twenty years of experience in government and the private sector. He is currently an Angel Investor and regulatory strategy consultant with a focus on MedTech and Venture Capital firms. Mr. Ulmer previously served as Vice President, Regulatory Affairs and Quality Assurance at Implant Direct, a Danaher Corporation operating company. He led efforts to shorten global registration timelines, improved product quality by process optimization and achieve best-in-class department engagement scores. Kwame has served in progressive leadership roles at the US Food and Drug Administration (FDA) and personally evaluated over 1,000 medical technologies.

Amit Vohra, PhD, MBA
President & CEO, Promaxo, Inc.

2Dr. Amit Vohra is President and CEO of Promaxo, a medical device company developing and commercializing an office-based and cost effective MRI scanner with high spatial resolution. Amit is a serial entrepreneur, business strategist and advisor to several healthcare and technology startups. He is a Partner in Advanced Biopharma Consulting, a management consultancy offering strategic business development and commercialization services in the life sciences space. He also serves as an advisor to Fanisko and TriOcula, and a strategy consultant to Precision Biopsy and Weinberg Medical Physics. Prior to Promaxo, Amit was the CEO/President of Convergent Life Sciences wherein he took a MRI-US fusion product, for targeted laser ablation of soft tissue cancer, through FDA clearance within 18 months of Company formation. Previously, as VP of Strategy and Operations at Eigen, he led the development and successful commercialization of two class II medical devices in the prostate biopsy space. In 2009, Amit co-founded Navya Biomedical Technologies, a biotechnology company using proprietary polyhydroxy fullerenes (PHF) for non-invasive imaging and destruction of solid tumors. Amit has a Doctorate in Mechanical Engineering from University of Florida, and an Executive MBA (Fuqua Scholar) from Duke University’s Fuqua School of Business.

2Jay Watkins
Chairman, Reflexion Medical

Jay Watkins has extensive experience founding and funding healthcare companies. He is an active individual investor and currently serves as Chairman of Shockwave Medical, Reflexion Medical and Recor Medical.  He teaches at the Stanford Byers Center for Biodesign and is a Lecturer in Management at the Graduate School of Business, Stanford University.

Mr. Watkins was co-founder and founding CEO of Origin Medsystems, a venture funded medical technology start-up acquired by Eli Lilly & Company. After Lilly formed Guidant, he joined the Management Committee and served as president of several divisions, including the Minimally Invasive Surgery Group, and Heart Rhythm Technologies. While President of the Cardiac and Vascular Surgery Group he initiated the development of a minimally invasive vein harvesting technology which has been used to treat more than two million patients worldwide. He also co-founded Gynecare, which was acquired by Johnson and Johnson. At Guidant, he formed and led Compass, Guidant’s corporate business development and new ventures group where he led venture investments in fourteen companies including Impella (acquired by Abiomed) and Intuitive Surgical (NASDAQ: ISRG).

Prior to founding Origin, Mr. Watkins held management positions in several start-ups, including Microgenics Corporation (acquired by Boehringer Mannheim), and was a consultant with McKinsey & Company. Mr. Watkins received his MBA from Harvard Business School and his undergraduate degree from Stanford University.

2Kevin Wasserstein
Founder & CEO, Neurotechnology Innovations Translator (NIT)

Kevin co-founded the NIT with Dr. Rezai, after a distinguished career spanning over 20 years in venture capital and operating roles specializing in building medical device companies from concept to commercialization. Kevin brings an experienced and practiced hand to NIT, with roles spanning investment and board leadership, executive leadership, engineering, business development, and marketing. Prior to founding NIT, Kevin founded MentorCatalyst to pursue his passion for MedTech company-building and for working intimately with entrepreneurs with a craftsman-styled approach to working with startup MedTech teams, deeply engaging on a select few startup medical device companies, providing comprehensive leadership and guidance. Prior to NIT and MentorCatalyst, Kevin spent eleven years as a Managing Director at Versant Ventures where he focused on investing in and building early stage medical device companies, and participated in the Firm’s investments in over 100 healthcare companies across 3 different investment funds, with investment allocations of over $1.1 B in capital. Kevin currently serves, or has served, in board or advisory roles with companies which include Acclarent (acquired: Johnson & Johnson), Autonomic Technologies, Cereve, Eargo, LipoSonix (acquired: Medicis), Lutonix (acquired: Bard), Microfabrica, Neoguide Systems (acquired: Intuitive Surgical), Oculeve (acquired: Allergan), Respicardia, Rox Medical, Second Sight Medical (NASDAQ:  EYES), St. Francis Medical (acquired: Kyphon), and The Innovation Factory.

Kevin previously held numerous operating leadership roles, including marketing and business development at Guidant Corporation, business development at Heartstream, and engineering development and management at Hughes Aircraft Company. Kevin holds both Bachelor’s and Master’s degrees in Mechanical Engineering, specializing in product design, as well as an MBA, all from Stanford University.

2Roderick Young
CyberHeart, Inc.

Rod Young is the CEO and Chairman of the Board of Directors of CyberHeart, Inc., a Company that he and Dr. Thomas Fogarty founded more than 12 years ago. He has over 25 years of executive experience in the medical device industry.

Before CyberHeart, Mr. Young served as a Venture Partner at Three Arch Partners from 2006 to 2014. Before Three Arch Partners, he was Founder, President and CEO of Vivant Medical, a microwave ablation company that was acquired by Covidien. He was also CEO of Focus Surgery, Inc., a pioneer in the development of products using high intensity focused ultrasound. Earlier in his career, Mr. Young was Chairman and CEO of General Surgical Innovations, Inc. (GSII), President of Toshiba America MRI, Inc., President and COO of Diasonics, and Chief Financial Officer of Raychem Corporation.

Mr. Young received a Bachelor of Science degree in Industrial Engineering from Stanford University and a Master’s Degree in Business Administration from Harvard Business School.